McLaren Partners with AbbVie for US Grand Prix Initiative

Collaboration Announcement at COTA

This weekend, the excitement of Formula 1 returns to Austin, Texas, with the United States Grand Prix at Circuit of the Americas (COTA). In a significant move, McLaren has revealed a partnership with AbbVie, a global biopharmaceutical leader, aiming to raise awareness and support for individuals living with immune-mediated conditions.

The Race to Innovate Campaign

Launched on October 20, AbbVie will come on board as an Official Pharmaceutical Partner for the McLaren Mastercard Formula 1 Team, marking the beginning of their collaboration during the US Grand Prix. This partnership will kick off the 'AbbVie Race to Innovate' campaign, which is designed to link McLaren's on-track achievements to philanthropic efforts for patients with autoimmune diseases.

Under this initiative, AbbVie pledges to contribute $10,000 for every 10 Constructors' Championship points received by McLaren, symbolizing the approximate 10% of the global population affected by autoimmune diseases. These contributions will benefit patient advocacy groups worldwide that educate and support individuals dealing with such conditions.

Shared Vision for Progress

Matt Dennington, Co-Chief Commercial Officer at McLaren Racing, expressed enthusiasm about the new partnership, stating, "We’re excited to welcome AbbVie at a pivotal time for our team ahead of the United States Grand Prix. This collaboration represents two organizations that are committed to progress, both on the racetrack and in advancing vital medical science." He also mentioned the aim of sharing inspiring stories that reveal the hard work behind such advancements.

Despite operating in distinct domains, McLaren and AbbVie share a common goal of overcoming complex challenges through teamwork, precision, and innovation.

Tracie Haas, Senior Vice President of Corporate Affairs at AbbVie, remarked, "Even though AbbVie and McLaren function in entirely different sectors, our commitment to continuous improvement and addressing intricate challenges unites us. As a key player in immunology for nearly three decades, we are eager to spotlight our dedication to patients on a global scale through this initiative. Every ten points scored by McLaren will translate into essential support for those living with immune-mediated diseases and their advocates."

Impact and Legacy

AbbVie is not new to sports collaborations; they maintain a partnership with Major League Baseball, donating $20 for each strikeout, with contributions capped at $1 million annually to support Stand Up To Cancer.

Over the years, AbbVie has made leaps in immunology, offering treatment options for those dealing with various autoimmune diseases, while McLaren Racing continually strives to enhance performance through engineering feats and teamwork. Their combined efforts will not only showcase innovative narratives but also honor the breakthrough moments and human determination that fuel advancements in both healthcare and motorsport.

This collaboration is set to span the full 2027 Formula 1 season, showcasing storytelling and fan engagement that highlight their mutual quest for progress.

AbbVie aims to transform the standard of care for those living with immune-mediated conditions, helping them live unrestricted lives. With a history of groundbreaking contributions to immunology, the company treats over a million patients globally, with medicines approved in more than 175 countries across 20-plus diseases affecting both adults and children.

As AbbVie looks to build further on its legacy and usher in the next wave of innovation, its focus will remain on improving patient outcomes and enhancing access to its treatments.

Being based in North Chicago, Illinois, the collaboration's launch during one of the three Formula 1 World Championship stops in the United States seems perfectly timed and fitting.